ACHE and Alzheimer disease: Indeed, in 2014 the FDA approved a fixed-dose combination of the anti-AD drugs donepezil and memantine (Namzaric®), and other drug combinations are currently being tested in clinical trials, in most cases involving an AChE inhibitor and/or memantine [17].